Клиническое значение антител к комплексу фосфатидилсерин/протромбин

Классическими серологическими маркерами антифосфолипидного синдрома (АФС) являются антитела к кардиолипину, антитела к 2-гликопротеину 1 и волчаночный антикоагулянт. Продолжает обсуждаться польза исследования других антифосфолипидных антител, не включенных в классификационные критерии, для улучшения диагностики аутоиммунной тромбофилии. В обзоре приведены данные литературы об исследовании антител к протромбину и комплексу фосфатидилсерин/протромбин у пациентов с системной красной волчанкой и АФС.

1. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010 Oct 30;376(9751):1498-509. doi: 10.1016/S0140-6736(10)60709-X

2. Решетняк ТМ, Чельдиева ФА, Нурбаева КС и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21.

3. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 Mar 14;368(11):1033-44. doi: 10.1056/NEJMra1112830.

4. Насонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литтера; 2004. С. 36.

5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.

6. Bertolaccini ML. Antibodies to prothrombin. Lupus. 2012 Jun;21(7):729-31. doi: 10.1177/0961203312443299.

7. Чельдиева ФА, Решетняк ТМ, Лила АМ. Антифосфолипидные антитела и их клиническое значение. Тромбоз, гемостаз и реология. 2021;(2):4-15.

8. Bertolaccini ML, Gomez S, Pareja JF, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005 Nov;64(11):1639-43. doi: 10.1136/ard.2005.035824.

9. Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011 Feb;20(2):191-205. doi: 10.1177/0961203310397082.

10. Bradacova P, Slavik L, Ulehlova J, et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines. 2021 Feb 8; 9(2):166. doi: 10.3390/biomedicines9020166.

11. Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005 Feb;93(2):289-97. doi: 10.1160/TH04-06-0382.

12. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 Sep;43(9):1982-93. doi: 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2.

13. Galli M, Beretta G, Daldossi M, et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997 Mar;77(3):486-91.

14. Chinnaraj M, Planer W, Pengo V, Pozzi N. Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Adv. 2019 Jun 11;3(11):1738-49. doi: 10.1182/bloodadvances.2019030932.

15. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993 May 15;81(10):2618-25.

16. Matsuda J, Saitoh N, Gohchi K, et al. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol. 1994 Sep;47(1):5 6-8. doi: 10.1002/ajh.2830470112.

17. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 1995 Oct 15; 86(8):3083-9.

18. Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993 Apr 10;341(8850):923-5. doi: 10.1016/0140-6736(93)91213-6.

19. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol. 2000 Mar;108(4):871-5. doi: 10.1046/j.1365-2141.2000.01948.x.

20. Острякова ЕВ, Решетняк ТМ, Айсина РБ, и др. Уровни плазминогена и ингибитора активатора плазминогена 1-го типа при антифосфолипидном синдроме. Терапевтический архив. 2012;84(5):50-7.

21. Jones DW, Gallimore MJ, MacKie IJ, et al. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000 Sep;110(3):721-6. doi: 10.1046/j.1365-2141.2000.02251.x.

22. Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost. 2001 Jan;85(1):57-62.

23. Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol. 2003 Feb;120(4):618-26. doi: 10.1046/j.1365-2141.2003.04161.x.

24. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001 Jul;86(1):83-91.

25. Chinnaraj M, Pengo V, Pozzi N. A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. Front Immunol. 2021 Sep 8;12:741589. doi: 10.3389/fimmu.2021.741589.

26. Решетняк ВИ, Журавель СВ, Кузнецова НК и др. Система гемостаза в норме и при трансплантации печени (обзор). Общая реаниматология. 2018;14(5):58-84.

27. Loeliger EA. Prothrombin as cofactor for circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh. 1959;(3):237–56.

28. Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983 Apr; 61(4):684-92.

29. Fujiwara K, Shimizu J, Tsukahara H, Shimada A. Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulinA vasculitis: a report of Japanese sibling cases and review of the literature. Rheumatol Int. 2019 Oct;39(10):1811-9. doi: 10.1007/s00296-019-04404-7.

30. Pengo V, Denas G, Bison E, et al; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res. 2010 Aug; 126(2):150-3. doi: 10.1016/j.thromres.2010.05.018.

31. Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996 May;75(5):721-4.

32. McDonnell T, Wincup C, Buchholz I, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020 Jan;39:100610. doi: 10.1016/j.blre.2019.100610.

33. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003 Oct 15;102(8):2717-23. doi: 10.1182/blood-2002-11-3334.

34. Sciascia S, Sanna G, Murru V, et al. Antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014 Feb;111(2):354-64. doi: 10.1160/TH13-06-0509.

35. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994 May 15;83(10):2878-92.

36. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988 Aug;72(2):512-9.

37. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005 Jun;3(6):1231-8. doi: 10.1111/j.1538-7836.2005.01295.x.

38. Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology. 2007;212(7):557-65. doi: 10.1016/j.imbio.2007.02.001.

39. Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013 Jul;56(2-3):432-8. doi: 10.1007/s12026-013-8421-z.

40. Zigon P, Cucnik S, Ambroћi A, et al. Antibodies to phosphatidylserine/prothrombin complex as an additional diagnostic marker of APS? Lupus. 2012 Jun;21(7):790-2. doi: 10.1177/0961203312444173.

41. Kondratieva L, Reshetnyak T, Alexandrova E, Novikov A, Lipatova N, Dobrovolskiy A, Nasonov E. The level of protrombin and antiprotrombin antibodies in patients with the antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2006;65:67.

42. Bizzaro N, Ghirardello A, Zampieri S, et al Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007 Jun;5(6):1158-64. doi: 10.1111/j.1538-7836.2007.02532.x.

43. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 Jun;93(6):1147-52. doi: 10.1160/TH04-12-0839.

44. Zigon P, Cucnik S, Ambroћi A, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol. 2013;2013:724592. doi: 10.1155/2013/724592.

45. Tselios K, Sarantopoulos A, Gkougkourellas I, Boura P. The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients. Front Neurol. 2013 Jun 4;4:66. doi: 10.3389/fneur.2013.00066.

46. Mullen MT, Messe SR, Kasner SE, et al. Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort. Front Neurol. 2012 Sep 28;3:137. doi: 10.3389/fneur.2012.00137.

47. Sanfelippo MJ, Joshi A, Schwartz S, et al. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or Beta-2-glycoprotein I. Lupus. 2013 Nov;22(13):1349-52. doi: 10.1177/0961203313497120.

48. Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012 Dec;10(12):2512-8. doi: 10.1111/jth.12014.

49. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009 Dec 2;302(21):2345-52. doi: 10.1001/jama.2009.1757.

50. Sciascia S, Cosseddu D, Montaruli B, et al. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011 Aug;70(8):1517-8. doi: 10.1136/ard.2010.145177.

51. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012 Feb;64(2):504-12. doi: 10.1002/art.33340.

52. Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 Aug; 52(8):1397-403. doi: 10.1093/rheumatology/kes388.

53. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2013 Jan;72(1):142-3. doi: 10.1136/annrheumdis-2012-201985.